Ajai Chari

Search results

• Experimental cancer therapy shows success in more than 70% of patients in global clinical trials;

  Ajai Chari

  16/02/23

  1 item of Media coverage

  Press/Media

• New drugs, if approved, could have big impact in 2023

  Ajai Chari

  27/01/23

  1 item of Media coverage

  Press/Media

• Chari Spotlights Efficacy of Talquetamab and Next Steps for Exploration in R/R Multiple Myeloma

  Ajai Chari

  12/01/23

  1 item of Media coverage

  Press/Media

• ‘Super-exciting’ novel bispecific impressing in myeloma

  Ajai Chari

  9/01/23

  1 item of Media coverage

  Press/Media

• ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

  Ajai Chari

  4/01/23

  1 item of Media coverage

  Press/Media

• New treatment showed encouraging results against bone marrow cancer

  Ajai Chari

  23/12/22

  1 item of Media coverage

  Press/Media

• Experimental Cancer Therapy Shows Success in More than 70% of Patients

  Ajai Chari

  22/12/22

  1 item of Media coverage

  Press/Media

• New Blood Cancer Therapy Gives a New Lease on Life To 73% of Patients

  Ajai Chari

  19/12/22

  1 item of Media coverage

  Press/Media

• Talquetamab: New drug may offer hope for those with hard-to-treat blood cancer

  Ajai Chari

  16/12/22

  1 item of Media coverage

  Press/Media

• Talquetamab: New drug may offer hope for those with hard-to-treat…

  Ajai Chari

  16/12/22

  1 item of Media coverage

  Press/Media

• Mount Sinai Hospital: Experimental Cancer Therapy Shows Success In More Than 70 Percent Of Patients In Global Clinical Trials

  Ajai Chari

  14/12/22

  1 item of Media coverage

  Press/Media

• Experimental cancer immunotherapy has over 70% response rate

  Ajai Chari

  13/12/22

  2 items of Media coverage

  Press/Media

• ‘Exciting’ responsiveness to talquetamab for r/r MM

  Ajai Chari

  13/12/22

  2 items of Media coverage

  Press/Media

• Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

  Ajai Chari

  10/12/22 → 13/12/22

  11 items of Media coverage

  Press/Media

• Antibody Treatment Makes Inroads Against Multiple Myeloma

  Ajai Chari

  12/12/22 → 13/12/22

  104 items of Media coverage

  Press/Media

• News New Cancer Drug Achieves 73% Response Rate in Patients A new immunotherapy has proven successful in 73% of multiple myeloma (MM) cancer patients in a Phase II clinical trial.

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• Medical Bulletin 12/December/2022

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• Antibody Treatment Makes Inroads Against Multiple Myeloma.(talquetamab)

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• High Response Rates With Talquetamab in Advanced Myeloma

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• Mount Sinai: Experimental Cancer Therapy Shows Success in More Than 70 Percent of Patients in Global Clinical Trials

  Ajai Chari

  12/12/22

  1 item of Media coverage

  Press/Media

• Experimental cancer therapy shows 73 pc success rate in trials: Study

  Ajai Chari

  10/12/22 → 12/12/22

  5 items of Media coverage

  Press/Media

• Experimental cancer therapy shows success in

  Ajai Chari

  11/12/22

  1 item of Media coverage

  Press/Media

• Talquetamab Continues to Elicit High Treatment Responses in a Heavily Pre-treated Multiple Myeloma Population

  Ajai Chari

  10/12/22

  2 items of Media coverage

  Press/Media